Pharma& /
Product Business
pharma& Schweiz GmbH to buy Clovis Oncology's Product Business
- Terms
- Not stated
- Stage
- Agreement signed




What happened
Clovis Oncology, Inc. entered into an asset purchase agreement with pharma& Schweiz GmbH on April 5, 2023, for the Product Business associated with Rubraca (rucaparib). The agreement provides for an upfront payment of $70,000,000, with additional payments tied to regulatory milestones and later sales.
The transaction is subject to approval by the Court.
The source
Everything on this page comes from the source below.
pharma& Schweiz GmbH to buy Clovis Oncology's Product Business
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly